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Abstract
Background: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis was first described in 2005 in association
with ovarian teratoma. The diagnostic workup of this common autoimmune encephalitis includes cerebrospinal
fluid analysis, electroencephalography, magnetic resonance imaging (MRI), and fluorodeoxyglucose positron
emission tomography (FDG-PET). In addition to standard diagnostics, we performed metabolic investigations using
proton magnet resonance spectroscopy (1H-MRS).
Case presentation: We describe the case of a non-limbic anti-NMDAR encephalitis with a long course of disease
(21 months). Laboratory diagnostics showed antibodies against NMDAR; an MRI revealed unspecific findings. 1H-MRS
indicated a hypoglutamatergic state in the left prefrontal cortex associated with a left hemispherical hypometabolism
on FDG-PET. Despite the long course of disease, immunosuppressive therapy with methylprednisolone and
azathioprine led to almost complete remission of clinical symptoms. Clinical improvement developed in parallel
with remarkable normalization of cerebral glucose metabolism on FDG-PET.
Conclusion: This case of long-lasting extra-limbic anti-NMDAR encephalitis is of high clinical relevance. First, it
illustrates that a very good outcome is possible even if adequate therapy is started only 21 months after the onset of
severe symptoms. Second, it provides valuable insights into the pathophysiology of such anti-NMDAR encephalitis;
these insights prove that anti-NMDAR encephalitis is linked not only to hyperglutamatergic signals but also to
hypoglutamatergic states. These findings, contradictory at first glance, can be integrated within the model of
excitatory/inhibitory imbalance and local area network inhibition.
Keywords: NMDA-receptor, Anti-NMDA-receptor-encephalitis, Glutamate, Magnetic resonance spectroscopy,
Fluorodeoxyglucose positron emission tomography
Background
Immunological encephalopathies (IE) are increasingly rec-
ognized in psychiatry as rare but still important causes of
clinical syndromes, which often present as atypical psych-
oses or affective disorders. IE may also present as a clas-
sical affective or psychotic syndrome without the hallmarks
of organic causes. In this paper, we want to illustrate
this new and complex clinical issue with respect to
anti-N-methyl-D-aspartate receptor (NMDAR) enceph-
alitis by presenting a remarkable, severe, and chronic
case of IE with positive outcome.
Anti-NMDA receptor encephalitis
The anti-NMDAR encephalitis was first described in 2005
in association with ovarian teratoma [1, 2], and was
followed by an still increasing number of case reports and
case series. In 2013, Titulaer and colleagues described 577
patients in the hitherto existing largest cohort study [3].
Some authors claim that anti-NMDAR encephalitis is the
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second most frequent autoimmune encephalitis, after
acute demyelinating encephalomyelitis [4].
Pathophysiologically, the initiation of anti-NMDAR-
antibody production has yet to be understood in detail.
In accordance with current theories, lymphocyte produc-
tion is stimulated by a peripheral initiator, such as a
tumor or infection. The disruption of the blood–brain
barrier allows the passage of immune cells into the cen-
tral nervous system (CNS) and leads to the clonal ex-
pansion of lymphocyte populations in the CNS, resulting
in intrathecal antibody production [5]. Antibody binding
to the NR1 subunit of the NMDA receptor leads to the
internalization of the NMDA receptor via a cross-linking
process with anti-Fab antibodies [6–8]. Internalization
creates a reversible NMDAR hypofunction without the
destruction of neurons or synapses [7, 9].
The clinical course of anti-NMDAR encephalitis is
characterized by different phases of the disease: 1) pro-
dromal period with headache, fever, or nausea; 2) psychi-
atric period with anxiety, paranoia, delusions, short-term
memory loss, disintegration of language and sometimes
mutism; 3) reduced consciousness; 4) hypoventilation; 5)
seizures; 6) autonomic instability with, for example,
hyperthermia, tachycardia, or urinary incontinence and
dyskinesia; and 7) recovery in approximately 75 % or
death [8, 10, 11]. In 60 % of patients, anti-NMDAR en-
cephalitis is paraneoplastic, most often associated with
ovarian teratoma [10]. The diagnostic workup includes
cerebrospinal fluid (CSF) analysis, electroencephalog-
raphy (EEG) and magnetic resonance imaging (MRI).
Common differential diagnosis (especially infectious
ones) should be clarified, and tumor screening should al-
ways be included in the diagnostic work up. The CSF
examination shows initial abnormalities in 80 % of pa-
tients; protein concentration and white blood cell
(WBC) counts are generally increased in a moderate
way. CSF specific oligoclonal bands can be found in
60 % of patients. An intrathecal synthesis of anti-NMDA
receptor antibodies is the most specific indicator [8].
EEG is abnormal in over 90 % of patients, and often
shows diffuse slow activity [8, 10]. In 30 % of patients,
a unique electrographic pattern called “extreme delta
brush” was observed [12, 13]. In 50 % of the cases, the
MRI has no pathological findings, while T2 or FLAIR
hyperintensity is found in different regions in the
remaining 50 % of cases [8]. Some studies showed ab-
normalities on fluorodeoxyglucose positron emission
tomography (FDG-PET) or single-photon emission
computed tomography [14–16].
Proton magnetic resonance spectroscopy (1H-MRS)
might be another diagnostic tool to investigate anti-
NMDAR encephalitis by measuring absolute concentra-
tions of glutamate (Glu), glutamine (Gln), and the com-
bined Glu and Gln signal, which is abbreviated as Glx.
Although randomized trials for the treatment of anti-
NMDAR encephalitis are lacking, high-dose intravenous
corticosteroids, plasma exchange, intravenous immuno-
globulins, azathioprine and monoclonal antibodies (e.g.,
rituximab) are commonly used [17].
Neurometabolic imaging
The FDG-PET visualizes regional neuronal activity by
measuring cerebral glucose (Glc) metabolism. However,
only 1H-MRS allows non-invasive and non-radioactive
measurement of Glu metabolism. 1H-MRS is a MR tech-
nique, that takes advantage of the fact that the resonance
frequency of certain molecules reflects their structure and,
thereby, their identity. 1H-MRS allows the absolute quan-
tification of Glx, phosphorylcholine and glycerophosphor-
ylcholine (t-Cho), N-acetylaspartate (NAA), creatine (Cre)
and myo-inositol (mI). Glu is the major excitatory neuro-
transmitter in the human brain [18], while Gln is its stor-
age and precursor form in astrocytes [19]. NAA is a
marker of neuronal and axonal integrity. t-Cho is a marker
for cell membrane turnover. Cre is often used as a concen-
tration reference substance based on its constancy with re-
spect to many pathologies. Finally, 1H-MRS allows the
detection of mI, which is seen as a glial marker and part of
the phosphatidyl-inositol second messenger system [20].
Case presentation
Specific characteristics
We present the case of a patient with an anti-NMDAR
encephalitis, with a left prefrontal hypoglutamatergic
status as measured with single-voxel 1H-MRS associated
with a left hemispheric hypometabolism shown by FDG-
PET. Despite the long duration of the disease, immuno-
suppressive therapy was successful.
Medical history
The patient is a 31-year-old woman who had worked
successfully as a business controller for years. Twenty-
one months prior to final diagnosis (day 0, onset), she
experienced the first signs of personality change for ap-
proximately two weeks (mood changes and compulsive
behaviors). Two months later, she experienced an epilep-
tic seizure (for the first time), affective destabilization,
cognitive deficits, and aggressiveness. Examination of the
CSF showed an increased WBC count (23 /μl) and an el-
evated protein concentration (487 mg/l). No infectious
cause was identified, and the MRI showed no patho-
logical findings. Treatment was initiated with ceftriaxone
and aciclovir for possible pathogenic agents, and cloba-
zam and valproate for seizures. Despite treatment, the
patient developed increasing mood changes, disorga-
nized agitated behavior, partial amnesia, disinhibition,
and ongoing aggressiveness. Additionally, she developed
delusional symptoms and delirious states, which were
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treated with antipsychotic medication and benzodiaze-
pines, as several physicians involved in the case manage-
ment preferred the diagnosis of schizophrenia. One
month later (~day 90, onset), the patient developed a
catatonic state with distinctive waxy flexibility and no re-
action to strong pain stimuli. At that time, the diagnosis
of catatonic schizophrenia was made. Two months later
(~day 150, onset), the condition had improved, and the
patient presented with a loss of energy, anxiety, and de-
celerated thinking, but without delusions, hallucinations
or catatonic states. No further antipsychotic therapy was
prescribed. Nearly one year later (~day 500, onset), the
patient attended a neurological rehabilitation center. At
that time, she still presented with loss of energy and pro-
nounced difficulties in concentration. Furthermore, at
that time, she was completely withdrawn socially. Be-
cause of psychotic and epileptic exacerbations, the diag-
nostic investigations were repeated (~day 540, onset).
WBC count (20/μl) and protein concentration (550 mg/
l) in the CSF were still elevated. A long-term EEG exam-
ination revealed a left temporal and right hemispherical
brain dysfunction without epileptiform patterns. In the
MRI, right temporo‐occipital signal alterations were de-
tected. A treatment with aciclovir, with the addition of
piperacillin, was again unsuccessful. Psychotic symptoms
increased and were treated again with antipsychotic
drugs and high doses of tranquilizers. Meanwhile, anti-
convulsive medication was changed to oxcarbazepine
and lamotrigine. Neither medication was tolerated, due
to leukopenia, thrombopenia, and exanthema; therefore,
monotherapy was continued with valproate. The state of
health deteriorated progressively with enuresis and an
inability to eat, drink, and carry out personal hygiene.
Twenty months after the first symptoms, the patient was
admitted to the university clinic of psychiatry & psycho-
therapy Freiburg for further investigations.
Clinical presentation
On admission, the patient presented in a tired but fully
conscious and oriented status. She showed difficulties in
concentration, loss of memory, and disturbed speech
production. On the first day, the patient already showed
states of altered consciousness, mutism, and bizarre be-
havior. She answered questions with laughing, repeated
single syllables (echolalia, palilalia), displayed fidgeting
movements (right hand), showed ocular muscle contrac-
tions (left), was smacking her lips and displaying stereo-
typical movements. The patient was repeatedly frozen
and showed symptoms of waxy flexibility.
Diagnostic results
In the CSF analysis, we found a blood–brain barrier disturb-
ance (protein: 561 mg/l, albumin-quotient: 8.7), normal cell
count (1/μl), and no intrathecal immunoglobulin synthesis.
Serological screening for antibodies against neuronal cell sur-
face antigens showed antibodies against the NMDA receptor.
The analysis was performed in the reference laboratory at the
Weatherall Institute of Molecular Medicine at John Radcliffe
Hospital (Oxford, UK). EEG analysis showed an intermittent
delta focus over the right central areas. In an additional inde-
pendent component analysis of the EEG, we were able to de-
scribe three components: 1) right and left frontotemporal
delta waves; 2) a deep right temporal generator; and 3) a cen-
tral component including theta frequencies. MRI showed no
specific findings; especially the hippocampal regions and
structures of limbic system were without pathological find-
ings. Moderate perisylvic/temporal accentuated atrophy was
found (Fig. 1). On FDG-PET, global cortical hypometabolism
of the left hemisphere was detected. A less pronounced hypo-
metabolism was also detected on the right side, particularly of
the temporal lobe. Cerebellar hypometabolismwas found pre-
dominantly on the right side (most likely indicating crossed
cerebellar diaschisis) (Fig. 2). 1H-MRS was performed in the
prefrontal cortex (PFC) on both sides, using the standard
single-voxel spectroscopy (voxel size 8 ml) Table 1. For spec-
troscopic analysis, the well-established and investigator-
independent LCModel (linear combination of model
spectra) algorithm was used (www.s-provencher.com/
pages/lcmodel.shtml) [21, 22]. In the PFC of the hypome-
tabolic left hemisphere, we found distinct lower Glx
Fig. 1 Magnet resonance imaging (MRI) findings. MRI only shows a moderate perisylvic/temporal accentuated atrophy
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concentrations compared with the opposite side. Glx/Cr
ratios were also significantly decreased.
Therapeutic and clinical course
A diagnosis of anti-NMDAR encephalitis was established
nearly 21 months after onset on the basis of typical clinical
symptoms and the serological detection of antibodies
against the NMDA receptor. We started an initial treat-
ment with plasma exchange over 2 weeks (5 sessions) and
prednisone (70 mg/d). However, this treatment did not
lead to any improvement; therefore, after 10 days, we
began a high-dose steroid pulse therapy (methylpred-
nisolone 500 mg i.v./day for 5 days) and subsequently,
a low-dose oral cortisone tapering until replacement
with azathioprine as chronic maintenance therapy.
Additionally, the antiepileptic medication was changed
from valproate to levetiracetam. During and after the
steroid pulse therapy, daily improvement was visible.
Language production normalized and mood swings and
disorganized behavior disappeared. The patient was dis-
charged from the psychiatric department to the neuro-
psychiatric rehabilitation.
A second FDG-PET five months after the start of steroid
treatment (~day 790, onset) indicated a nearly regular
metabolism (Fig. 2). A slight frontal hypometabolism
remained, probably due to frontal accentuated atrophy.
Fig. 2 Fluorodeoxyglucose positron emission tomography (FDG-PET) findings. The initial FDG-PET scan (08/2010) depicted a global cortical
hypometabolism of the left hemisphere, and, to a lesser extent, also of the right hemisphere; on the right side, hypometabolism was primarily
located in the temporal lobe. Cerebellar hypometabolism was pronounced on the right side (most likely indicating crossed cerebellar diaschisis). The
lower FDG-PET scan was acquired after successful immunosuppressive therapy (01/2011), indicating a nearly regular cerebral metabolism. A slight
frontal hypometabolism remained most likely secondary due to frontal accentuated atrophy. Pronounced occipital metabolism is explainable by scan
acquisition with open eyes. Both FDG-PET scans were performed at the Department of Nuclear Medicine of the University Hospital Freiburg
after injection of 240 MBq 18FDG each (Gemini TF64 PET scanner, Philips Healthcare, The Netherlands)
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In cognitive testing before discharge, slight deficits,
particularly in working memory and mental flexibility,
were still present. The repeated gynecological tumor
screening for teratoma showed no pathological findings
up to date.
Conclusion
Characteristics of our case report
We present the case of a 31-year-old woman with severe
neuropsychiatric symptoms which were classified as
schizophrenia or catatonic schizophrenia by several clini-
cians involved in case management but who in fact was
suffering from an anti-NMDAR encephalitis. Neurometa-
bolic investigations showed a left prefrontal hypoglutama-
tergic status in 1H-MRS associated with a left hemispheric
hypometabolism on FDG-PET. To our knowledge, this is
the first report of cortical hypoglutamatergic in vivo me-
tabolism in anti-NMDAR encephalitis, illustrating that this
mechanism might be of pathogenetic relevance in the
genesis of psychiatric symptoms in such constellations.
Despite the long duration of the neuroinflammatory
process (21 months), immunosuppressive therapy was
still successful. Clinical improvement paralleled the
normalization of the metabolism on FDG-PET.
FDG-PET in autoimmune encephalitis
FDG-PET provides greater sensitivity for autoimmune
encephalitis (78 %) compared with MRI (63 %) [23]. In
our case report, we observed non-specific changes with
MRI and remarkable abnormalities with the FDG-
PET. In a retrospective analysis of FDG-PET findings
with regard to autoimmune encephalitis, a significant
association between autoantibody type and PET findings
was described: in patients with autoantibodies against
intracellular antigens, mainly mesiotemporal abnormal-
ities were found, whereas normal findings or abnormal-
ities outside the mesiotemporal region were more often
detected in patients with autoantibodies against surface
antigens, such as antibodies against the NMDA receptor
[23]. Specifically, patients with anti-NMDAR encephal-
itis showed frontal and temporal Glc hypermetabolism as-
sociated with occipital hypometabolism (frontotemporal-
to-occipital gradient). This pattern was positively associ-
ated with clinical disease severity. On longitudinal mea-
surements of two patients, a normalization of cerebral
Glc metabolism was identified [24]. We detected deviat-
ing FDG-PET results; in our case study, a global cortical
hypometabolism was found in the left hemisphere, and,
to a lesser degree, also in the right hemisphere. Moreover,
cerebellar hypometabolism was identified, particularly on
the right hemisphere, likely secondary to crossed cerebel-
lar diaschisis. In our case, cortical hypometabolism might
be the consequence of the long-term process which be-
came apparent on FDG-PET 21 months after onset of the
disease. By contrast, hypermetabolism in the frontotem-
poral regions might be an indicator of an acute disease
phase [15], as Glc metabolism increases in active inflam-
mation [25]. Consequently, in the study from Leypoldt
and colleagues showing frontotemporal hypermetabolism,
there was a distinctly shorter median time (median time
was 10 weeks; range from 10 to 30 weeks) from the onset
of the disease until FDG-PET imaging [24]. However, it is
important to note that cortical hypometabolism did not
indicate irreversible neuronal injury or post-inflammatory
Table 1 Magnetic resonance spectroscopy (1H-MRS) results
Left prefrontal cortex Right prefrontal cortex
Metabolite concentration (in IU) (CRLB) Metabolite ratio (/Cre) Metabolite concentration (in IU) (CRLB) Metabolite ratio(/Cre)
Glx 5.673 (12 %) 1.129 7.424 (8 %) 1.576
Cre 5.023 (3 %) 1.0 4.710 (3 %) 1.0
t-Cho 1.238 (3 %) 0.246 1.217 (3 %) 0.258
NAA + NAAG 6.783 (3 %) 1.350 5.802 (3 %) 1.232
mI 3.815 (5 %) 0.760 3.295 (5 %) 0.699
The MRS spectrum from the left prefrontal cortex shows lower concentrations of Glx compared with the opposite side. Glutamatergic hypometabolism
correlated with a distinct hypometabolism in FDG-PET in this region; TR = 3000; TE = 30; NS = 64; voxel size = 8.0 mL. Abbreviations: CRLB = Cramér-Rao
lower bounds; IU = Institutional Units; Glx = glutamate + glutamate;
Cre = creatine; t-Cho = phosphorylcholine + glycerophosphorylcholine; NAA +NAAG =N-acetylaspartate + N-acetyl-aspartyl glutamate; mI =myo-inositol
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residuum in our case, because metabolism largely recov-
ered upon treatment in parallel to clinical improvement.
1H-MRS in autoimmune encephalitis
To our knowledge, only two 1H-MRS measurements in
anti-NMDAR encephalitis have been published to date
[26, 27]. In the first case, NAA signals were initially de-
creased and normalized in the clinical course [26]. In
the second case, reduced NAA concentrations were ob-
served in the basal ganglia and thalamus at an early
stage. Despite reduced NAA levels, MRI and EEG find-
ings were unremarkable in this case. In late stage and
after resolution of involuntary movements, NAA signals
normalized [27]. In our case, we only detected a ten-
dency towards higher NAA concentrations in the hypo-
metabolic left hemisphere. However, we found evidence
of decreased Glx signals and Glx/Cre ratios in the hypo-
metabolic left hemisphere compared with the right side.
It is tempting to speculate that this underlies the ob-
served, reversible hypometabolism on FDG-PET, which
may be due to a persistent NMDAR hypofunctional state
after the initial acute inflammatory and hypermetabolic
phase observed by others. The reversibility of this
process is likely the reason for the good prognosis of our
patient, even though the pathogenic process went un-
treated for nearly 21 months. The decrease of NMDA
receptors directly correlates with the antibody titers [8].
Manto and colleagues performed in vivo experiments
using Glu. They were able to identify increased Glu con-
centrations in the extracellular space. The increase was
dose-dependent and much more pronounced with puri-
fied IgG [28].
Excitatory/inhibitory dysbalance and local area network
inhibition
The findings of extracellular hyperglutamatergic states
reported by Manto et al. [28] and our findings of hypo-
glutamatergic signal in 1H-MRS seem to be contradictory
at first glance. However, they might well be integrated
within the theoretical framework of excitatory/inhibitory
dysbalance and local area network inhibition [29–31].
Similar results indicating a change from hyper- to hypo-
glutamatergic status are well known in epilepsy research.
Excitatory seizure activity initially leads to an acute in-
crease in Glx concentrations and a subsequent decrease
in these concentrations over the course of the disease
[29, 30, 32, 33]. A state of neuronal network instability
as seen in epilepsy can be associated with local area hy-
perexcitability and hyperinhibition [31]. Therefore, we
speculate that a model of a neuronal excitatory/inhibitory
imbalance might explain the plethora of neuropsychiatric
symptoms that can be observed in the course of NMDR
encephalitis: Initial hyperglutamatergic states can be
interpreted as an indicator of cortical over-excitation,
whereas hypoglutamatergic states in the further course
(after months) of the disease might be a sequel of over-
inhibition of cortical brain areas, possibly triggered by
the preceding over-excitation. We have recently put
forward a model of local area network inhibition (LANI
hypothesis) that is capable of explaining how states
of excitatory/inhibitory dysbalances might translate
pathogenetically into a plethora of neuropsychiatric
symptoms typically seen in “organic psychiatric disor-
ders” [31]. Such a model is also capable of explaining
the symptoms of our patient. Initial and intercurrent
hyperglutamatergic states might be linked to her hyper-
excitability and symptoms such as seizures, whereas
hypoglutamatergic states might be the cause for hyper-
inhibition and symptoms like her mutistic and delirious
states.
Neuroinflammation and glutamatergic metabolism
Furthermore, it is important to recognize that neuro-
inflammation is itself associated with altered gluta-
matergic metabolism. For example, the reduction of
extracellular glutamate concentrations, through the
intake of Glu into astrocytes, is disturbed during the
inflammatory process [34]. Disturbed glutamate sig-
nals have also been shown to occur in neuroinflamma-
tory diseases, such as HIV encephalopathy [35]. Thus,
it seems reasonable to combine Glc (FDG-PET) and
Glu (1H-MRS) measurements in cases in which anti-
NMDAR encephalitis is suspected.
Summary
We presented the case of a 31-year-old woman with
anti-NMDAR encephalitis. Neurometabolic investiga-
tions showed a left prefrontal hypoglutamatergic status
on 1H-MRS associated with left hemispheric hypome-
tabolism on FDG-PET. This case is remarkable be-
cause, to our knowledge, this is the first report on in
vivo hypoglutamatergic status in anti-NMDAR enceph-
alitis. The non-invasive measurement of the Glx sig-
nals via 1H-MRS might directly provide insights into
the pathomechanism of anti-NMDAR encephalitis. In
further studies, the combination of EEG, MRI, FDG-
PET, and 1H-MRS should be performed during differ-
ent stages of disease progression. Finally—and, clinic-
ally, even more important—our case report illustrates
that even a retarded initiation of immunosuppressive
therapy might be effective, and could lead to nearly full
clinical remission.
Consent
The patient has given her consent for the details of the
case report and for the figures to be published.




OS: Consulting and lecture fees, grant and research support from Bayer Vital
GmbH, Biogen Idec, Genzyme, Merck Serono, Novartis, Sanofi-Aventis and
Teva.
SR: Consulting and lecture fees, grant and research support from Bayer Vital
GmbH, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis and Teva. He is a




IM: Lecture fees from Bracco Imaging Deutschland GmbH, Germany; Roche
Pharma AG, Germany; UCB Pharma GmbH, Germany.
PTM: Funding of an ongoing research study by GE.
LTVE: Advisory boards, lectures, or travel grants within the last three years: Eli
Lilly, Janssen-Cilag, Novartis, Shire, UCB, GSK, Servier, Janssen, and Cyberonics.
Authors’ contributions
EP and ZW treated the patient. DE and EP conducted the data analysis and
wrote the paper. LTVE contributed to the manuscript preparation. IM
critically reviewed the MR results, and PTM, the FDG-PET results. OS und SR
performed the CSF analysis. TL supported the 1H-MRS-analysis. LTVE, OS, SR,
SM, ZW, TL, IM and PTM were crutially involved in the theoretical discussion
and performing of the manuscript. All authors read and approved the final
version of the manuscript.
Author details
1Section of Experimental Neuropsychiatry, Department for Psychiatry&
Psychotherapy, University Medical Center Freiburg, Hauptstr. 5, 79104
Freiburg, Germany. 2Freiburg Brain Imaging, University Medical Center
Freiburg, Breisacher Str. 64, 79106 Freiburg, Germany. 3Department of
Neurology, University Medical Center Freiburg, Breisacher Str. 64, 79106
Freiburg, Germany. 4Department of Radiology, Medical Physics, University
Medical Center Freiburg, Breisacher Str. 64, 79106 Freiburg, Germany.
5Department of Neuroradiology, University Medical Center Freiburg,
Breisacher Str. 64, 79106 Freiburg, Germany. 6Department of Nuclear
Medicine, University Medical Center Freiburg, Hugstetter Str. 64, 79106
Freiburg, Germany.
Received: 2 February 2015 Accepted: 6 July 2015
References
1. Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J.
Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in
ovarian teratoma. Ann Neurol. 2005;58(4):594–604.
2. Dalmau J, Tüzün E, Wu H, Masjuan J, Rossi JE, Voloschin A, et al.
Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated
with ovarian teratoma. Ann Neurol. 2007;61(1):25–36.
3. Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al.
Treatment and prognostic factors for long-term outcome in patients with
anti-NMDA receptor encephalitis: an observational cohort study. Lancet
Neurol. 2013;12(2):157–65.
4. Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, et al.
Causes of encephalitis and differences in their clinical presentations in
England: a multicentre, population-based prospective study. Lancet Infect
Dis. 2010;10(12):835–44.
5. Ramanathan S, Mohammad SS, Brilot F, Dale RC. Autoimmune encephalitis:
Recent updates and emerging challenges. J Clin Neurosci. 2014;21(5):722–30.
6. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-
NMDA-receptor encephalitis: case series and analysis of the effects of
antibodies. Lancet Neurol. 2008;7(12):1091–8.
7. Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, et al. Cellular and
synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci.
2010;30(17):5866–75.
8. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon
R. Clinical experience and laboratory investigations in patients with
anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63–74.
9. Bien CG, Bauer J. Pathophysiologie antikörperassoziierter ZNS-Erkrankungen.
Nervenarzt. 2013;84(4):466–70.
10. Prüss H, Dalmau J, Arolt V, Wandinger K. Anti-NMDA-Rezeptor-Enzephalitis.
Ein interdisziplinäres Krankheitsbild. Nervenarzt. 2010;81(4):396. 398, 400, passim.
11. Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with
diseases of the CNS: new developments and future challenges. Lancet
Neurol. 2011;10(8):759–72.
12. Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D.
Extreme delta brush: a unique EEG pattern in adults with anti-NMDA
receptor encephalitis. Neurology. 2012;79(11):1094–100.
13. Rosenfeld MR, Titulaer MJ, Dalmau J. Paraneoplastic syndromes and
autoimmune encephalitis: Five new things. Neurol Clin Pract. 2012;2(3):215–23.
14. Maeder-Ingvar M, Prior JO, Irani SR, Rey V, Vincent A, Rossetti AO. FDG-PET
hyperactivity in basal ganglia correlating with clinical course in
anti-NDMA-R antibodies encephalitis. J Neurol Neurosurg Psychiatr.
2011;82(2):235–6.
15. Pillai SC, Gill D, Webster R, Howman-Giles R, Dale RC. Cortical hypometabolism
demonstrated by PET in relapsing NMDA receptor encephalitis. Pediatr Neurol.
2010;43(3):217–20.
16. Llorens V, Gabilondo I, Gómez-Esteban JC, Agundez M, Mendibe M, Bergara
JC, et al. Abnormal multifocal cerebral blood flow on Tc-99 m HMPAO
SPECT in a patient with anti-NMDA-receptor encephalitis. J Neurol.
2010;257(9):1568–9.
17. Peery HE, Day GS, Dunn S, Fritzler MJ, Prüss H, de Souza C, et al. Anti-NMDA
receptor encephalitis. The disorder, the diagnosis and the immunobiology.
Autoimmun Rev. 2012;11(12):863–72.
18. Novotny EJ, Fulbright RK, Pearl PL, Gibson KM, Rothman DL. Magnetic
resonance spectroscopy of neurotransmitters in human brain. Ann Neurol.
2003;54 Suppl 6:S25–31.
19. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts
and coupling constants for brain metabolites. NMR Biomed.
2000;13(3):129–53.
20. Ross B, Bluml S. Magnetic resonance spectroscopy of the human brain.
Anat Rec. 2001;265(2):54–84.
21. Provencher SW. Estimation of metabolite concentrations from localized in
vivo proton NMR spectra. Magn Reson Med. 1993;30(6):672–9.
22. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with
LCModel. NMR Biomed. 2001;14(4):260–4.
23. Baumgartner A, Rauer S, Mader I, Meyer PT. Cerebral FDG-PET and MRI
findings in autoimmune limbic encephalitis: correlation with autoantibody
types. J Neurol. 2013;260(11):2744–53.
24. Leypoldt F, Buchert R, Kleiter I, Marienhagen J, Gelderblom M, Magnus T, et al.
Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-
aspartate receptor encephalitis: distinct pattern of disease. J Neurol
Neurosurg Psychiatr. 2012;83(7):681–6.
25. Sekigawa M, Okumura A, Niijima S, Hayashi M, Tanaka K, Shimizu T.
Autoimmune focal encephalitis shows marked hypermetabolism on
positron emission tomography. J Pediatr. 2010;156(1):158–60.
26. Yamamoto S, Koide Y, Fujiwara M, Nakazawa K, Takahashi Y, Hara H.
Subacute encephalitis associated with anti-glutamate receptor antibodies:
serial studies of MRI, 1H-MRS and SPECT. Rinsho Shinkeigaku.
2008;48(3):196–201.
27. Kataoka H, Dalmau J, Taoka T, Ueno S. Reduced N-acetylaspartate in the
basal ganglia of a patient with anti-NMDA receptor encephalitis. Mov
Disord. 2009;24(5):784–6.
28. Manto M, Dalmau J, Didelot A, Rogemond V, Honnorat J. In vivo effects of
antibodies from patients with anti-NMDA receptor encephalitis: further evidence
of synaptic glutamatergic dysfunction. Orphanet J Rare Dis. 2010;5:31.
29. Tebartz van Elst L, Maier S, Fangmeier T, Endres D, Mueller GT, Nickel K,
et al. Disturbed cingulate glutamate metabolism in adults with high-
functioning autism spectrum disorder: evidence in support of the
excitatory/inhibitory imbalance hypothesis. Mol Psychiatry.
2014;19(12):1314–25.
30. van Elst LT, Maier S, Fangmeier T, Endres D, Mueller GT, Nickel K, et al.
Magnetic resonance spectroscopy comparing adults with high functioning
autism and above average IQ. Mol Psychiatry. 2014;19(12):1251.
31. Tebartz van Elst L, Krishnamoorthy ES, Schulze-Bonhage A, Altenmüller D,
Richter H, Ebert D, et al. Local area network inhibition: a model of a
potentially important paraepileptic pathomechanism in neuropsychiatric
disorders. Epilepsy Behav. 2011;22(2):231–9.
32. Doelken MT, Mennecke A, Stadlbauer A, Kecskeméti L, Kasper BS, Struffert T,
et al. Multi-voxel magnetic resonance spectroscopy at 3 T in patients with
idiopathic generalised epilepsy. Seizure. 2010;19(8):485–92.
Endres et al. BMC Psychiatry  (2015) 15:186 Page 7 of 8
33. Zahr NM, Crawford ELF, Hsu O, Vinco S, Mayer D, Rohlfing T, et al. In vivo
glutamate decline associated with kainic acid-induced status epilepticus.
Brain Res. 2009;1300:65–78.
34. Takaki J, Fujimori K, Miura M, Suzuki T, Sekino Y, Sato K. L-glutamate
released from activated microglia downregulates astrocytic L-glutamate
transporter expression in neuroinflammation: the 'collusion' hypothesis for
increased extracellular L-glutamate concentration in neuroinflammation.
J Neuroinflammation. 2012;9:275.
35. Chang L, Munsaka SM, Kraft-Terry S, Ernst T. Magnetic resonance spectroscopy
to assess neuroinflammation and neuropathic pain. J Neuroimmune
Pharmacol. 2013;8(3):576–93.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Endres et al. BMC Psychiatry  (2015) 15:186 Page 8 of 8
